ADC Therapeutics SA (NYSE:ADCT) Stock Has Consensus Target Price of $5.00 According to Brokerages

Shares of ADC Therapeutics SA (NYSE:ADCT) have received a consensus rating of “Hold” from the six analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $5.00.

Several research analysts recently commented on the company. Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Guggenheim reduced their price target on ADC Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ADC Therapeutics in a research report on Friday, July 17th.

ADC Therapeutics Stock Performance

NYSE ADCT opened at $1.72 on Wednesday. The firm has a 50 day simple moving average of $1.17 and a 200-day simple moving average of $2.05. ADC Therapeutics has a one year low of $0.78 and a one year high of $4.98. The firm has a market cap of $218.95 million, a price-to-earnings ratio of -2.60 and a beta of 1.86.

ADC Therapeutics (NYSE:ADCT) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.11. The business had revenue of $19.25 million during the quarter, compared to analyst estimates of $18.89 million. Equities analysts predict that ADC Therapeutics will post -0.80 EPS for the current fiscal year.

Institutional Trading of ADC Therapeutics

A number of large investors have recently made changes to their positions in the company. R Squared Ltd acquired a new position in ADC Therapeutics during the 1st quarter worth approximately $38,000. Quantinno Capital Management LP increased its position in shares of ADC Therapeutics by 36.0% in the 1st quarter. Quantinno Capital Management LP now owns 14,719 shares of the company’s stock valued at $55,000 after purchasing an additional 3,894 shares during the last quarter. AXQ Capital LP acquired a new stake in shares of ADC Therapeutics in the 2nd quarter valued at $29,000. Sei Investments Co. raised its holdings in shares of ADC Therapeutics by 45.6% in the 1st quarter. Sei Investments Co. now owns 33,461 shares of the company’s stock valued at $125,000 after purchasing an additional 10,472 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in shares of ADC Therapeutics in the 1st quarter valued at $290,000. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

ADC Therapeutics Company Profile

ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.